
Why Y Fountain?
Breakthrough technology meets world-class science to redefine longevity research.
Patterned High-Throughput Screening
Our proprietary patterned screening platform enables drug screening over 4,000 times more efficiently than traditional methods, dramatically accelerating anti-aging compound discovery.
Proprietary AI Foundation Models
AI models trained on human blood omics data accurately predict survival outcomes, enabling precise assessment of biological age and real-time evaluation of intervention effectiveness.
World-Class Scientific Team
Founded by a UCSF biotechnology professor whose decades of cellular aging research form our scientific backbone. Our team includes inventors of proprietary screening technology, biotech professionals, pharmaceutical chemists, and AI specialists.
Our team
Scientists, founders, and advisors dedicated to cellular rejuvenation and longevity

Hao Li, Ph.D.
Co-Founder & Patent Inventor
Professor, Biochemistry and Biophysics, UCSF Director, Hillblom Center for the Biology of Aging, UCSF Investigator, CZ Biohub
Dr. Li received his Ph.D in theoretical physics from MIT, and has over 15 years of experience leading a research team focusing on bioinformatics, systems biology and aging. Dr. Li developed the first microfluidic system to analyze aging in single cells, and is the primary inventor of the high-throughput microfluidic single-cell analysis chip. Having published >90 peer reviewed papers, Dr. Li leads research programs supported by NIH, Packard foundation, Hillblom foundation, and CZ Biohub. Dr. Li serves as the advisory board member of Max Planck Society, American Federation for Aging Research, and Member of the Faculty of 1000.

Changhui Deng, Ph.D.
Co-Founder & Patent Inventor
Associate Professional Researcher, Biochemistry and Biophysics, UCSF
Dr. Deng received his Ph. D. in biochemistry and molecular biology, UC Riverside. An expert in genetics and synthetic biology, Dr. Deng developed the daughter arresting program (DAP) that forms the basis of high-throughput microfluidic systems. Dr. Deng has published 13 peer reviewed papers and holds two US patents (pending).

Yun Bai, Ph.D.
Chief Financial Officer lead
Dr. Bai received his Ph. D. from Columbia University in the field of budding yeast research and DNA repair. Besides biological research, Dr. Bai also worked in the financial industry at Lehman Brothers and JP Morgan, and as a multitude of expertise in biotech research, finance and compliance.

Michelle Arkin, Ph.D.
Scientific Advisor
Vice Dean for Research Technology and Entrepreneurship, UCSF Thomas William and Frederick John MacWilliam Distinguished Professor, UCSF Executive Director, Small Molecule Discovery Center (SMDC), UCSF Professor, Department of Pharmaceutical Chemistry, UCSF
Dr. Arkin is the Thomas William and Frederick John MacWilliam Distinguished Professor at UCSF. Dr. Arkin serves as the Vice Dean of Research Technology and Entrepreneurship, and the Executive Director of the Small Molecule Discovery Center, a collaborative research and core lab that includes a high-throughput screening facility and medicinal chemistry. Dr. Arkin is a renowned expert on medicinal chemistry, chemical biology, protein-protein interactions, screening, cancer, and neglected disease, and neglected diseases.

Brian Kennedy, Ph.D.
Scientific Advisor
Distinguished Professor of Biochemistry & Physiology, Yong Loo Lin School of Medicine, National University of Singapore Director, Centre for Healthy Longevity, National University Health System (NUHS) Programme Director, Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, NUS Director, Asian Centre for Reproductive Longevity and Equality, Yong Loo Lin School of Medicine, NUS Adjunct Senior Principal Investigator, Singapore Institute for Clinical Sciences, A*STAR Adjunct Professor, Leonard Davis School of Gerontology, USC
Dr. Brian Kennedy is a Distinguished Professor in the Departments of Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University Singapore. He serves as the Director for the Centre for Healthy Longevity at the National University Health System and Director of the Healthy Longevity Translational Research Programme and the Asian Centre for Reproductive Longevity and Equality. Prior to that, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging. Dr. Kennedy's research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend the healthspan, the disease-free and highly functional period of life.
Supported by leading institutions and research partners
We collaborate with world-class organizations advancing the science of longevity





